CIDP
MCID: CHR070
MIFTS: 57

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Categories: Immune diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

Name: Chronic Inflammatory Demyelinating Polyradiculoneuropathy 12 52 58 36 15 37 17
Chronic Inflammatory Demyelinating Polyneuropathy 52 53 58 17
Cidp 52 58
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 71
Polyradiculoneuropathy Chronic Inflammatory Demyelinating 54

Characteristics:

Orphanet epidemiological data:

58
chronic inflammatory demyelinating polyneuropathy
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5213
KEGG 36 H01527
ICD9CM 34 357.81
MeSH 43 D020277
NCIt 49 C84636
SNOMED-CT 67 128209004
ICD10 32 G61.81
ICD10 via Orphanet 33 G61.8
UMLS via Orphanet 72 C0393819
Orphanet 58 ORPHA2932
UMLS 71 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NIH Rare Diseases : 52 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. Symptoms often include tingling or numbness (first in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes, fatigue, and abnormal sensations. Other symptoms may include pain, difficulty swallowing (dysphagia ), and double vision (diplopia ). CIDP is thought to be caused by the immune system mistakenly attacking and damaging the myelin sheath (protective cover of nerve fibers) of the peripheral nerves. CIDP is closely related to Guillain-Barre syndrome (GBS) and is considered the "chronic counterpart" of GBS. Treatment may include corticosteroids , immunosuppressant drugs, plasma exchange, physical therapy , and/or intravenous immunoglobulin (IVIG) therapy. Left untreated, 30% of people with CIDP will progress to wheelchair dependence.

MalaCards based summary : Chronic Inflammatory Demyelinating Polyradiculoneuropathy, also known as chronic inflammatory demyelinating polyneuropathy, is related to polyneuropathy and guillain-barre syndrome. An important gene associated with Chronic Inflammatory Demyelinating Polyradiculoneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Immunoglobulin G and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and spinal cord, and related phenotypes are areflexia and paresthesia

Disease Ontology : 12 An autoimmune disease of peripheral nervous system that is characterized by inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering (myelin sheath) over the nerves. This affects how fast the nerve signals are transmitted and leads to loss of nerve fibers.

NINDS : 53 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder, which is sometimes called chronic relapsing polyneuropathy, is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women. It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

KEGG : 36 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a polyneuropathy that is often disabling, with more than 50% of patients reported as having temporary disability, and about 10% eventually becoming persistently disabled. The core clinical features are a chronic progressive or relapsing and remitting, symmetrical, and sensory and motor polyradiculoneuropathy causing weakness of proximal and distal muscles. The etiology is suspected to be of autoimmune origin, and the diagnosis is typically based on clinical history, neurologic examination, electrophysiologic studies, cerebrospinal fluid (CSF) studies, and pathologic examination. CIDP often responds to immune therapies including corticosteroids, plasma exchange, and high-dose intravenous immunoglobulin (IVIg).

Wikipedia : 74 Chronic inflammatory demyelinating polyneuropathy is an acquired immune-mediated inflammatory disorder... more...

Related Diseases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 548)
# Related Disease Score Top Affiliating Genes
1 polyneuropathy 31.4 PMP22 MPZ MBP CD59 ALB
2 guillain-barre syndrome 31.3 PMP22 MPZ MBP HLA-DRB1 ALB
3 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.1 IL17A IL10 IFNG
4 hereditary neuropathies 31.1 PMP22 MPZ MBP
5 sensory peripheral neuropathy 31.0 PMP22 MPZ ALB
6 foot drop 31.0 PMP22 MPZ
7 neurosyphilis 30.9 IL17A IL10
8 myasthenia gravis 30.9 MBP IL10 IFNG
9 optic neuritis 30.8 MPZ MBP IL10 HLA-DRB1
10 autoimmune neuropathy 30.8 PMP22 MPZ ICOSLG
11 chronic graft versus host disease 30.8 IL10 IFNG ALB
12 graft-versus-host disease 30.7 IL10 IFNG HLA-DRB1
13 roussy-levy hereditary areflexic dystasia 30.7 PMP22 MPZ
14 autoimmune peripheral neuropathy 30.6 MPZ ICOSLG
15 cutaneous lupus erythematosus 30.6 IL17A IL10 IFNG
16 intestinal tuberculosis 30.6 IFNG ALB
17 transverse myelitis 30.5 MBP IL17A IL10
18 hepatitis a 30.4 IL10 IFNG ALB
19 discoid lupus erythematosus 30.4 IL10 HLA-DRB1
20 cryoglobulinemia 30.4 IL10 IFNG HLA-DRB1
21 mixed connective tissue disease 30.4 IL10 IFNG HLA-DRB1
22 viral hepatitis 30.3 IL10 IFNG HLA-DRB1 ALB
23 brucellosis 30.3 IL17A IL10 IFNG
24 neuromyelitis optica 30.2 MBP IL17A HLA-DRB1 CD59
25 autoimmune hepatitis 30.2 IL10 HLA-DRB1 ALB
26 syphilis 30.2 IL17A IFNG HLA-DRB1 ALB
27 acquired immunodeficiency syndrome 30.2 MBP IL10 IFNG ALB
28 corneal disease 30.2 IL17A IL10 ALB
29 chronic mucocutaneous candidiasis 30.1 IL17A IL10 IFNG
30 candidiasis 30.1 IL17A IL10 IFNG
31 exanthem 30.1 IL10 IFNG ICOSLG ALB
32 graves' disease 30.0 IFNG ICOSLG HLA-DRB1 CCL5
33 internuclear ophthalmoplegia 30.0 MBP IFNB1
34 myositis 30.0 IL17A IFNG ICOSLG HLA-DRB1
35 neuritis 30.0 PMP22 MPZ MBP IL10 IFNG CCL5
36 lyme disease 30.0 IL17A IFNB1 HLA-DRB1
37 radiculopathy 29.9 PMP22 IL17A IL10 CCL5 CCL4
38 hashimoto thyroiditis 29.8 IL17A IL10 IFNG HLA-DRB1
39 primary biliary cirrhosis 29.8 IL17A IL10 IFNG HLA-DRB1 ALB
40 pulmonary tuberculosis 29.7 IL10 IFNG HLA-DRB1 CCL4 ALB
41 rubella 29.6 IL10 IFNG IFNB1 HLA-DRB1
42 sarcoidosis 1 29.6 IFNG ICOSLG HLA-DRB1 CCL5 CCL4
43 psoriasis 29.5 IL17A IL10 IFNG HLA-DRB1 CCL5
44 common variable immunodeficiency 29.4 IL10 IFNG ICOSLG HLA-DRB1 CCL19
45 crohn's disease 29.4 IL17A IL10 IFNG ICOSLG HLA-DRB1 ALB
46 allergic hypersensitivity disease 29.3 IL17A IL10 IFNG ICOSLG CCL5
47 arthritis 29.3 IL17A IL10 IFNG HLA-DRB1 CCL5 ALB
48 lymphoma, non-hodgkin, familial 29.3 PRF1 IL10 ICOSLG HLA-DRB1 CD59
49 diarrhea 29.3 IL10 IFNG IFNB1 ALB
50 meningitis 29.3 IL17A IL10 IFNG CCL5 CCL4 ALB

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Human phenotypes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

58 31 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 areflexia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001284
2 paresthesia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003401
3 unsteady gait 58 31 hallmark (90%) Very frequent (99-80%) HP:0002317
4 segmental peripheral demyelination/remyelination 58 31 hallmark (90%) Very frequent (99-80%) HP:0003481
5 sensory ataxia 58 31 hallmark (90%) Very frequent (99-80%) HP:0010871
6 motor conduction block 58 31 hallmark (90%) Very frequent (99-80%) HP:0012078
7 fatiguable weakness of proximal limb muscles 58 31 hallmark (90%) Very frequent (99-80%) HP:0030200
8 difficulty walking 58 31 frequent (33%) Frequent (79-30%) HP:0002355
9 hand muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0030237
10 difficulty climbing stairs 58 31 frequent (33%) Frequent (79-30%) HP:0003551
11 falls 58 31 frequent (33%) Frequent (79-30%) HP:0002527
12 spontaneous pain sensation 58 31 occasional (7.5%) Occasional (29-5%) HP:0010833
13 peripheral neuropathy 58 Very frequent (99-80%)
14 decreased nerve conduction velocity 58 Very frequent (99-80%)
15 sensory impairment 58 Very frequent (99-80%)
16 abnormal nerve conduction velocity 58 Very frequent (99-80%)
17 peripheral demyelination 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 CCL19 CCL5 CD59 IFNB1 IFNG IL10
2 immune system MP:0005387 9.73 ALB CCL19 CCL5 IFNB1 IFNG IL10
3 neoplasm MP:0002006 9.1 ALB IFNB1 IFNG IL10 PRF1 TBX21

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulin G Phase 4
2
tannic acid Approved Phase 3 1401-55-4
3
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
4
Mycophenolic acid Approved Phase 3 24280-93-1 446541
5
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
6 Fingolimod Hydrochloride Phase 3
7 Anti-Infective Agents Phase 3
8 Antitubercular Agents Phase 3
9 Anti-Bacterial Agents Phase 3
10 Antibiotics, Antitubercular Phase 3
11 Pharmaceutical Solutions Phase 2, Phase 3
12
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
13
Levetiracetam Approved Phase 2 102767-28-2 441341
14
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
15
Carmustine Approved, Investigational Phase 2 154-93-8 2578
16
Etoposide Approved Phase 2 33419-42-0 36462
17
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
18
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
19
Melphalan Approved Phase 2 148-82-3 460612 4053
20
rituximab Approved Phase 2 174722-31-7 10201696
21
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
22
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
23
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
24
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
25
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
26
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
27 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
28
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
29
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
30
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
31
Cortisone Experimental Phase 2 53-06-5 222786
32
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
33 Rozanolixizumab Investigational Phase 2 1584645-37-3
34 Interferon-beta Phase 2
35 interferons Phase 2
36 Adjuvants, Immunologic Phase 2
37 Micronutrients Phase 2
38 Trace Elements Phase 2
39 Alpha-lipoic Acid Phase 2
40 Vitamins Phase 2
41 Vitamin B Complex Phase 2
42 Antioxidants Phase 2
43 Thioctic Acid Phase 2
44 Folate Phase 2
45 Nutrients Phase 2
46 Vitamin B9 Phase 2
47 Anticonvulsants Phase 2
48 Antiviral Agents Phase 2
49 Etoposide phosphate Phase 2
50 Nitrogen Mustard Compounds Phase 2

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Active, not recruiting NCT03684018 Phase 4
3 An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
5 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
6 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
7 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
8 An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02293460 Phase 3 I10E
9 A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
10 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
12 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
13 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
14 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
15 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
16 Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy Completed NCT02638207 Phase 3 NewGam
17 Does the Mycophenolate Improve the Ability of Weaning Patients Off the Treatment in Chronic Inflammatory Demyelinating Polyradiculopathy (CIDP) Completed NCT02494505 Phase 3 Mycophenolate Mofetil;placebo
18 Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02955355 Phase 3
19 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Active, not recruiting NCT02549170 Phase 3
20 International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302" Terminated NCT02317562 Phase 3 I10E
21 Double-blind, Placebo-controlled, Randomised, Multicentre, Adaptive, Two-stage Phase 2/3 Study Evaluating Safety and Efficacy of Three Dosages of NewGam in CIDP Patients Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
22 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
23 Randomised, Double-blinded, Placebo-controlled Trial of Subcutaneous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
24 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
25 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy—A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
26 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
27 Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes Completed NCT02343211 Phase 2 Immunoglobulin
28 Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: a Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety. Completed NCT02637700 Phase 2 Intravenous Immunoglobulin;Placebo
29 A Pilot Study in a Double Blind, Randomized, Placebo-Controlled, Parallel-Group, 16 Week, Trial Design Evaluating the Efficacy and Safety of Levetiracetam 500 mg Tablets in Bid Administration (Daily Dose Ranging From 1000 mg to 3000 mg), in Adults (>18 Years of Ages) Suffering From Chronic Idiopathic Axonal Polyneuropathy Completed NCT00156689 Phase 2 levetiracetam
30 A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT03861481 Phase 2 Rozanolixizumab
31 A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Recruiting NCT04281472 Phase 2
32 High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases Recruiting NCT00716066 Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan;Prednisone
33 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Active, not recruiting NCT03864185 Phase 2
34 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Active, not recruiting NCT00278629 Phase 2
35 Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia Active, not recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
36 An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Enrolling by invitation NCT04051944 Phase 2 Rozanolixizumab
37 IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS) Enrolling by invitation NCT03919773 Phase 1, Phase 2 IVIG;Albumin
38 Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT04280718 Phase 2
39 Intravenous Immunoglobulin (IVIG) in the Treatment of Autoimmune Small Fiber Neuropathy Due to TS-HDS and FGFR-3 Antibodies: a Double Blinded Placebo-controlled Phase II Trial Not yet recruiting NCT04153422 Phase 2 Gammagard IVIG;Placebo
40 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
41 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
42 A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-06755347 AFTER SINGLE ASCENDING INTRAVENOUS INFUSIONS TO HEALTHY ADULT MALE PARTICIPANTS Recruiting NCT03275740 Phase 1 PF-06755347;Placebo comparator
43 Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells Unknown status NCT02404298 IVIg
44 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Unknown status NCT03397303
45 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Unknown status NCT02892890
46 A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT02465359 Immune Globulin Subcutaneous (Human)
47 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
48 Magnetic Resonance Imaging and Ultrasound Imaging of Peripheral Nerves in Patients Treated With Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Completed NCT02017769
49 A Multicenter Pilot Study to Determine Criteria for Evaluating the Effectiveness of Two Comparative Monitoring Methods in the Management of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Receiving Home-based Treatment With IVIg (Privigen®) Completed NCT03779828
50 "Clinical Study of Intravenous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy" Completed NCT00305266 intravenous gammaglobulin

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Immunoglobulins, Intravenous

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Chronic Inflammatory Demyelinating Polyradiculoneuropathy:
Hematopoietic stem cells for treatment of chronic inflammatory demyelinating polyneuropathy
Embryonic/Adult Cultured Cells Related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:
Bone marrow-derived hematopoietic stem cells PMIDs: 17277794

Genetic Tests for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

40
T Cells, Skin, Spinal Cord, Testes, Brain, Bone, Endothelial

Publications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

(show top 50) (show all 2335)
# Title Authors PMID Year
1
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. 61 54
16170091 2005
2
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. 61 54
11912115 2002
3
P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. 61 54
11558784 2001
4
Anti-PMP22 antibodies in patients with inflammatory neuropathy. 54 61
10713353 2000
5
Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. 61 54
10408537 1999
6
Abnormal motor unit firing rates in chronic inflammatory demyelinating polyneuropathy. 61
32402831 2020
7
Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients. 61
32299841 2020
8
Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment. 61
32364302 2020
9
Low interrater reliability of brachial plexus MRI in chronic inflammatory neuropathies. 61
32012299 2020
10
Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155. 61
32563125 2020
11
The Misdiagnosis of CIDP: A Review. 61
32219701 2020
12
High-Resolution Nerve Ultrasound to Assess Nerve Echogenicity, Fascicular Count, and Cross-Sectional Area Using Semiautomated Analysis. 61
32521091 2020
13
Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. 61
32200107 2020
14
Electrodiagnostic accuracy in polyneuropathies: supervised learning algorithms as a tool for practitioners. 61
32518996 2020
15
Safety and tolerability of therapeutic plasma exchange in autoimmune neurological diseases - a retrospective single-centre analysis. 61
32557528 2020
16
Recurrent Demyelinating Episodes as Sole Manifestation of Inherited CD59 Deficiency. 61
31752029 2020
17
Pathological Findings in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Single-Center Experience. 61
32560468 2020
18
Assessment of IL-38 Levels in Patients with Acquired Immune-Mediated Polyneuropathies. 61
32367504 2020
19
Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. 61
32404895 2020
20
Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells. 61
32375895 2020
21
Papilledema in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Pediatric Case and Review of the Literature. 61
32468920 2020
22
Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy. 61
32410146 2020
23
High Levels of Il-19 in Patients with Chronic Inflammatory Demyelinating Polyneuropathy. 61
32472395 2020
24
Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy. 61
32388856 2020
25
Quantitative sudomotor test helps differentiate transthyretin familial amyloid polyneuropathy from chronic inflammatory demyelinating polyneuropathy. 61
32217467 2020
26
Rituximab for chronic inflammatory demyelinating polyneuropathy-A potential therapeutic option. 61
32232860 2020
27
Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. 61
31922613 2020
28
A case of combined central and peripheral demyelination in Zambia. 61
31958671 2020
29
Immune-mediated inflammatory polyneuropathy overlapping Charcot-Marie-Tooth 1B. 61
32201027 2020
30
Impact of environmental factors and physical activity on disability and quality of life in CIDP. 61
32430573 2020
31
Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes. 61
32006783 2020
32
[Pitfalls for Diagnosis of Polyneuropathy by Nerve Conduction Study]. 61
32284466 2020
33
Epidemiology of chronic inflammatory demyelinating polyneuropathy in the South-Eastern area of Santiago, Chile. 61
32067826 2020
34
Use of Magnetic Resonance Neurography for Evaluating the Distribution and Patterns of Chronic Inflammatory Demyelinating Polyneuropathy. 61
32193896 2020
35
Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy. 61
32279669 2020
36
Antibody- and macrophage-mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates. 61
31769579 2020
37
Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care: A Review of Clinical and Laboratory Assessment Measures. 61
32338716 2020
38
Diagnosing peripheral neuropathy in South-East Asia: A focus on diabetic neuropathy. 61
32268012 2020
39
Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. 61
31959710 2020
40
RELEVANCE OF DIAGNOSTIC INVESTIGATIONS IN CHRONIC INFLAMMATORY DEMYELINATING POLIRADICULONEUROPATHY: DATA FROM THE ITALIAN CIDP DATABASE. 61
32343015 2020
41
Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. 61
32234705 2020
42
Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins. 61
32078921 2020
43
Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features. 61
32266541 2020
44
Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy. 61
31981273 2020
45
Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. 61
31571349 2020
46
Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy. 61
31766959 2020
47
Co-occurrence of Merkel Cell Carcinoma and Chronic Inflammatory Demyelinating Polyneuropathy. 61
32159728 2020
48
A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy. 61
31793666 2020
49
Abnormality of multimodal evoked potentials in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). 61
32212008 2020
50
Autoimmune Peripheral Neuropathies and Contribution of Antiganglioside/Sulphatide Autoantibody Testing. 61
32411930 2020

Variations for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Expression for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Pathways related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 IL17A IL10 IFNG IFNB1 ICOSLG HLA-DRB1
2
Show member pathways
13.12 IL17A IL10 IFNG IFNB1 HLA-DRB1 CCL5
3
Show member pathways
12.46 TBX21 IL17A IL10 IFNG HLA-DRB1
4
Show member pathways
12.44 PRF1 IL17A IL10 IFNG ICOSLG HLA-DRB1
5 12.41 TBX21 IL17A IL10 IFNG CCL5
6
Show member pathways
12.18 IL10 CCL5 CCL4 CCL19
7
Show member pathways
12.11 IL17A IL10 IFNG IFNB1
8 12.09 IL10 IFNG IFNB1 HLA-DRB1
9 11.83 IL10 IFNG CD59
10
Show member pathways
11.81 TBX21 IFNG HLA-DRB1 CCL4
11 11.77 PMP22 MPZ MBP
12
Show member pathways
11.76 TBX21 IL17A IL10 IFNG
13 11.64 IL17A IFNG HLA-DRB1 CCL5
14 11.6 IL10 IFNG IFNB1
15 11.53 TBX21 IL17A IL10 IFNG
16 11.25 IL10 CCL5 CCL4 CCL19
17
Show member pathways
11.24 IL10 IFNG CCL4
18 11.16 TBX21 IL17A IFNG
19 10.87 IL17A IL10 CCL5 CCL4 CCL19
20 10.72 IL10 IFNG IFNB1 HLA-DRB1
21 10.37 TBX21 PRF1 IFNG HLA-DRB1

GO Terms for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 PRF1 IL17A IL10 IFNG IFNB1 CD59
2 extracellular space GO:0005615 9.32 IL17A IL10 IFNG IFNB1 HLA-DRB1 CD59
3 compact myelin GO:0043218 9.16 PMP22 MBP

Biological processes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.84 HLA-DRB1 CCL5 CCL4 CCL19
2 cellular response to interferon-gamma GO:0071346 9.79 CCL5 CCL4 CCL19
3 response to toxic substance GO:0009636 9.78 MBP CCL5 CCL4
4 neutrophil chemotaxis GO:0030593 9.74 CCL5 CCL4 CCL19
5 chemokine-mediated signaling pathway GO:0070098 9.72 CCL5 CCL4 CCL19
6 myelination GO:0042552 9.65 PMP22 MPZ MBP
7 cytokine-mediated signaling pathway GO:0019221 9.63 IL17A IL10 IFNB1 CCL5 CCL4 CCL19
8 dendritic cell chemotaxis GO:0002407 9.62 CCL5 CCL19
9 monocyte chemotaxis GO:0002548 9.61 CCL5 CCL4 CCL19
10 negative regulation by host of viral transcription GO:0043922 9.6 CCL5 CCL4
11 immunological synapse formation GO:0001771 9.59 PRF1 CCL19
12 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.58 MBP IL10
13 positive regulation of MHC class II biosynthetic process GO:0045348 9.58 IL10 IFNG
14 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.56 IL17A IFNG
15 cellular response to interleukin-1 GO:0071347 9.56 IL17A CCL5 CCL4 CCL19
16 immune response GO:0006955 9.56 MBP IL17A IL10 IFNG HLA-DRB1 CCL5
17 positive regulation of interleukin-6 secretion GO:2000778 9.54 MBP IL17A IFNG
18 regulation of complement-dependent cytotoxicity GO:1903659 9.52 IL10 CD59
19 positive regulation of natural killer cell chemotaxis GO:2000503 9.51 CCL5 CCL4
20 lymphocyte chemotaxis GO:0048247 9.5 CCL5 CCL4 CCL19
21 positive regulation of killing of cells of other organism GO:0051712 9.49 PRF1 IFNG
22 positive regulation of interleukin-23 production GO:0032747 9.46 IL17A IFNG
23 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.4 TBX21 IFNB1
24 response to virus GO:0009615 9.1 TBX21 IFNG IFNB1 CCL5 CCL4 CCL19

Molecular functions related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine receptor binding GO:0042379 9.37 CCL5 CCL19
2 chemokine activity GO:0008009 9.33 CCL5 CCL4 CCL19
3 CCR5 chemokine receptor binding GO:0031730 9.32 CCL5 CCL4
4 CCR1 chemokine receptor binding GO:0031726 9.26 CCL5 CCL4
5 cytokine activity GO:0005125 9.17 IL17A IL10 IFNG IFNB1 CCL5 CCL4
6 CCR chemokine receptor binding GO:0048020 9.13 CCL5 CCL4 CCL19

Sources for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....